Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Inclusion Criteria:

Histologically confirmed* solid tumor, including any of the following:

Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET)
Osteosarcoma
Rhabdomyosarcoma
Neuroblastoma
High-grade astrocytoma
Low-grade astrocytoma
Glioblastoma multiforme
Ependymoma
Hepatoblastoma
Germ cell tumors of any site

Rare tumors of interest, including any of the following:

Soft tissue sarcoma
Hepatocellular carcinoma
Childhood/adolescent colorectal carcinoma
Childhood/adolescent renal cell carcinoma
Childhood/adolescent adrenocortical carcinoma
Childhood/adolescent nasopharyngeal carcinoma
Recurrent disease OR refractory to conventional therapy
Measurable disease by clinical exam, CT scan, MRI, or positron emission tomography
Performance status - Karnofsky 50-100% (for patients over age 10)
Performance status - Lansky 50-100% (for patients age 10 and under)
At least 8 weeks
Absolute neutrophil count ≥ 1,000/mm^3*
Platelet count ≥ 75,000/mm^3* (transfusion independent)
Hemoglobin ≥ 8.0 g/dL* (RBC transfusions allowed)
Granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow metastases or extensive prior radiotherapy allowed provided the above hematological criteria are met
Bilirubin ≤ 3 mg/dL

Creatinine based on age as follows:

≤ .8 mg/dL (for patients age 5 and under)
≤ 1.0 mg/dL (for patients age 6 to 10)
≤ 1.2 mg/dL (for patients age 11 to 15)
≤1.5 mg/dL (for patients age 16 to 21)
Creatinine clearance or radioisotope glomerular filtration rate > 20 mL/min
No uncontrolled seizure disorder
No uncontrolled infection
CNS toxicity ≤ grade 2
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Recovered from prior immunotherapy
At least 7 days since prior anticancer biologic therapy
More than 1 week since prior growth factors

At least 6 months since prior allogeneic stem cell transplantation

No evidence of active graft-vs-host disease
No concurrent immunomodulating agents
Recovered from prior chemotherapy
No prior oxaliplatin
Prior carboplatin or cisplatin allowed
More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
No other concurrent anticancer chemotherapy
Concurrent dexamethasone for CNS tumors allowed provided patient has been on a stable or decreasing dose for ≥ 1 week before study entry
Recovered from prior radiotherapy
At least 2 weeks since prior local palliative radiotherapy (small port)
At least 6 months since prior craniospinal radiotherapy
At least 6 months since prior radiotherapy to ≥ 50% of the pelvis
At least 6 weeks since other prior substantial radiotherapy to the bone marrow
Concurrent radiotherapy to localized painful lesions allowed provided ≥ 1 measurable lesion is not irradiated
No other concurrent investigational agents
No other concurrent anticancer agents